Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

Jung, Seung‐Hyun; Lee, Sung‐Eun; Kim, So-Hee; Yim, Seon‐Hee; Kim, Tae Woo; Min, Chang‐Ki; Chung, Yeun‐Jun

doi:10.3324/haematol.2017.168070

Cited by 23 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High levels of serum miR-214 and miR-135b were found in patients with MMBD, where they positively correlated with the severity of the bone lytic lesions and predicted worst PFS and OS [196]; accordingly, high expression of miR-214 was detected in exosomes and serum of osteoporotic than non-osteoporotic patients, thus suggesting its potential as biomarker for MMBD [197]. A pattern of five circulating miRNAs was significantly reduced in patients with relapsed/refractory MM and poor responders after treatment with lenalidomide plus low-dose dexamethasone [198]. A relative lower expression of miR-143, miR-144, miR-199 and miR-203 in both BM supernatant fluid and serum of MM patients was found as compared with healthy controls; in these patients, levels of the proteoglycan VCAN positively, whereas miRNAs negatively correlated with the severity of disease [199].…”

Section: Circulating Ncrnas In Pc Dyscrasiasmentioning

confidence: 95%

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias

Morelli

Gullà

Rocca

et al. 2020

Cancers

View full text Add to dashboard Cite

Despite substantial advancements have been done in the understanding of the pathogenesis of plasma cell (PC) disorders, these malignancies remain hard-to-treat. The discovery and subsequent characterization of non-coding transcripts, which include several members with diverse length and mode of action, has unraveled novel mechanisms of gene expression regulation often malfunctioning in cancer. Increasing evidence indicates that such non-coding molecules also feature in the pathobiology of PC dyscrasias, where they are endowed with strong therapeutic and/or prognostic potential. In this review, we aim to summarize the most relevant findings on the biological and clinical features of the non-coding RNA landscape of malignant PCs, with major focus on multiple myeloma. The most relevant classes of non-coding RNAs will be examined, along with the mechanisms accounting for their dysregulation and the recent strategies used for their targeting in PC dyscrasias. It is hoped these insights may lead to clinical applications of non-coding RNA molecules as biomarkers or therapeutic targets/agents in the near future.

show abstract

Section: Circulating Ncrnas In Pc Dyscrasiasmentioning

confidence: 95%

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias

Morelli

Gullà

Rocca

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Exosomes can be potential diagnostic biomarkers and facilitate the diagnosis and classification of diseases and contribute to the prediction of prognosis in cancer patients as well [16][17][18][19]. As an important component of exosomes, miRNAs vary in types and amounts among different exosomes and cells, and the abnormal expression of certain miRNAs is often associated with the clinical diagnosis.…”

Section: Mirna Related Potential Treatment Targets For MM In Exosomesmentioning

confidence: 99%

Potential Therapeutic Roles of Exosomes in Multiple Myeloma: A Systematic Review

Xia

Wang

et al. 2019

J. Cancer

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second most prevalent hematological malignancy. In spite of the remarkable progress in understanding the biology and therapy of MM, curing this disease remains difficult, which calls for more effective treatment strategies. As vital communicators between different cells, exosomes have been verified to be crucial to cancer diagnosis, treatment, and prognosis. Exosomes in MM patients show a different expression profile compared with those in healthy individuals. In this review, we summarize potential therapy roles exosomes may play in MM. The specific expression of certain components in exosomes may provide therapeutic targets. Moreover, tumor-derived exosomes and their modified products can be developed into vaccines for anti-tumor immunity. In addition, the natural nano structure of exosomes makes them excellent carriers for drug delivery. Thus, a more rigorous investigation into exosomes will pave the way for novel tumor therapies in MM patients.

show abstract

“…Thus, these two miRNAs in EVs were identified to be independent predictors for both progression-free and overall survival in MM. Six miRNAs (miR-26a-5p, miR-29c-3p, miR-30b-5p, miR-30c-5p, miR-193a-5p, and miR-331-3p) were significantly down-regulated in poor responders to lenalidomide with low-dose dexamethasone treatment [ 69 ]. Furthermore, down-regulation of several miRNAs, including miR-16-5p, miR-15a-5p, miR-20a-5p, and miR-17-5p, was observed in the patients with bortezomib resistance [ 70 ], thus circulating EVs carrying miRNAs may be used to predict drug resistance.…”

Section: Clinical Application Of Ev-associated Mirnas As Biomarkermentioning

confidence: 99%

A Challenge to Aging Society by microRNA in Extracellular Vesicles: microRNA in Extracellular Vesicles as Promising Biomarkers and Novel Therapeutic Targets in Multiple Myeloma

Kosaka¹,

Hattori

Ochiya³

2018

JCM

View full text Add to dashboard Cite

Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells and is the second most common hematological cancer. MM frequently occurs in the elderly population with the median age as the middle sixties. Over the last 10 years, the prognosis of MM has been dramatically improved by new therapeutic drugs; however, MM is still incurable. The pathogenesis of MM is still unclear, thus greater understanding of the molecular mechanisms of MM malignancy is desirable. Recently, microRNAs (miRNAs) were shown to modulate the expression of genes critical for MM pathogenesis. In addition, miRNAs are secreted via extracellular vesicles (EVs), which are released from various cell types including MM cells, and these miRNAs are involved in multiple types of cell-cell interactions, which lead to the malignancy of MM. In this review, we summarize the current knowledge regarding the role of miRNA secretion via EVs and of EVs themselves in MM development. We also discuss the potential clinical applications of EVs as promising biomarkers and new therapeutic targets for improving the outcome of MM, resulting in a brighter future for aging societies.

show abstract

Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

Cited by 23 publications

References 15 publications

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias

Potential Therapeutic Roles of Exosomes in Multiple Myeloma: A Systematic Review

A Challenge to Aging Society by microRNA in Extracellular Vesicles: microRNA in Extracellular Vesicles as Promising Biomarkers and Novel Therapeutic Targets in Multiple Myeloma

Contact Info

Product

Resources

About